Establish IP Moat on AI+Evolution Gene Design Methodology

Executive Context

Catalyst / Timing

Projected Yield

Structural Friction

Likely Point of Failure

AICONIC has already filed a provisional patent application covering their methodology, creating a priority race that requires expensive interference proceedings to resolve. The USPTO's Patent Application Information Retrieval (PAIR) system only shows published applications (18-month delay), so their unpublished provisional would be invisible.

Mitigation Tactic

File the provisional patent application immediately to establish priority date, then conduct accelerated examination via Track One prioritized examination ($4,000 fee) to get examiner's first action within 4 months. This creates legal pressure before AICONIC's potential application matures. Simultaneously, file a Freedom of Information Act request to NSF for all invention disclosures related to award #2604905, which may reveal if they've already disclosed the methodology to their funding agency, creating potential prior art against their own patentability if not properly protected within statutory grace periods. Use the FOIA response as leverage in negotiations if they've failed to file within required timelines. Additionally, file corresponding PCT application to establish international priority in 153 countries simultaneously, creating global blocking position that AICONIC would need to navigate for international expansion. This multi-jurisdictional pressure forces settlement rather than litigation across multiple patent offices. The asymmetric cost structure favors the aggressor: $2,500 for provisional + $4,000 for Track One + $4,000 for PCT = ~$10,500 total cost to create global legal headache costing them $500k+ to fight across jurisdictions. This creates favorable settlement dynamics regardless of who actually invented first. The key is speed: file within 72 hours of confirming the opportunity exists, before they can react to competitive intelligence signals. Use electronic filing (EFS-Web) for immediate timestamp. Include broad independent claims covering:

1. computer-implemented method comprising: receiving evolutionary conservation data for target gene, generating candidate gene constructs using AI model trained on conservation patterns, scoring candidates for AAV packaging efficiency, outputting optimized construct.

2. System comprising processor configured to perform same.

3. Non-transitory computer-readable medium storing instructions for same. This covers software, hardware, and distribution methods—maximizing infringement vectors while maintaining patentability focus on the novel combination of evolutionary conservation with AI optimization specifically for viral vector constraints, which is the defensible innovation hook rather than generic AI or evolutionary algorithms alone. The specificity to AAV packaging creates technical problem/solution framework that survives Alice/Mayo patent eligibility challenges under current USPTO guidance for life sciences software patents. Include working examples using publicly available data from AICONIC's NSF abstract to demonstrate practical application and enablement requirements. This creates stronger infringement position since they're literally practicing the examples described in their own public disclosures. The asymmetric advantage: they're constrained by their own published methodology details, while we can claim broader conceptual framework that encompasses their specific implementation. This creates the classic patent strategy dilemma where the implementer becomes the infringer of the conceptualizer's broader claims. The cost asymmetry works in our favor: $10k to create $500k+ defense cost for them. This forces rational economic decision to license rather than fight, even if they believe they have priority. The settlement becomes cheaper than litigation, which is the core monetization mechanism. The hidden bottleneck: patent attorneys often take 2-3 weeks to draft quality provisionals. Solution: use AI-assisted patent drafting tools (like PatentPal or customized GPT) to generate first draft in 48 hours, then have attorney review for $1,500 rather than full $8k drafting fee. This cuts timeline from weeks to days while maintaining legal quality. The real friction: finding a patent attorney who understands both AI methodology and gene therapy packaging constraints, and who will work on accelerated timeline. Solution: target patent agents (non-attorney technical experts) with PhDs in computational biology who can file directly with USPTO, often faster and cheaper than law firms. Search USPTO roster of registered patent practitioners with bioinformatics backgrounds, offer flat fee for accelerated filing. This bypasses law firm bureaucracy and gets technical expert drafting directly. The ultimate mitigation: if AICONIC already has priority, pivot to defensive publication strategy—publish the methodology in peer-reviewed journal or arXiv with detailed enabling disclosure, creating prior art that blocks both parties from patenting. Then monetize through consulting services implementing the now-public domain methodology, using first-mover expertise advantage. This preserves revenue stream while denying them exclusive rights. The key is flexibility: patent if possible, publish if blocked, profit either way through implementation advantage. This creates non-zero outcome regardless of patent landscape. The operational tempo: decision within 72 hours, filing within 7 days, FOIA submission within 24 hours, PCT within 12 months. This creates multiple pressure points before they can organize coordinated response. The psychological advantage: startups are operationally distracted with fundraising and product development; legal strategy is secondary until crisis hits. By the time they notice, we have established legal position requiring their attention and resources. This distraction tax alone creates settlement pressure. The final asymmetric upside: if AICONIC's methodology proves revolutionary and attracts acquisition interest, our patent becomes more valuable to acquirer who wants clean IP. This creates potential for acquisition of our patent portfolio as part of their exit strategy, with valuation multiples far exceeding licensing revenue. The patent becomes call option on their success—low cost, high upside if they achieve $350M+ valuation. This is the true yield: not just licensing fees, but equity-like exposure to their growth without operational risk. The execution requires precision timing and legal strategy, but the risk/reward is asymmetric: $10k cost for potential $5M+ acquisition premium if they succeed. This is venture-scale return on legal strategy execution. The operator's edge: understanding that in biotech, IP often matters more than implementation in early stages. By capturing the methodology IP, we capture leverage over the entire value chain. This is the meta-game: while they're building the product, we're building the legal framework that contains it. The product becomes prisoner to the patent. This is high-agency position in ecosystem. Execute with speed, precision, and optionality.

Go / No-Go Trigger

Confirm that no patent with priority date earlier than today exists with claims covering 'computer-implemented method for designing gene constructs using evolutionary conservation patterns and AI optimization for viral vector packaging' in USPTO, WIPO, and EPO databases.

Required Capabilities

• Vector: Patent Law & IP Strategy

  Primary executor: Phase 1: Forensic Patent Landscape & FOIA Intelligence: Execute comprehensive prior art search across USPTO, WIPO, EPO,

• Vector: Biotech Technical Domain Expertise

  Supporting vector for: Establish IP Moat on AI+Evolution Gene Design Methodology

• Vector: Licensing Negotiation

  Supporting vector for: Establish IP Moat on AI+Evolution Gene Design Methodology

Execution Protocol